Concepts (203)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 44 | 2024 | 2075 | 4.420 |
Why?
|
| Anti-Retroviral Agents | 12 | 2018 | 154 | 2.920 |
Why?
|
| Infectious Disease Transmission, Vertical | 12 | 2020 | 255 | 2.180 |
Why?
|
| Malawi | 30 | 2023 | 426 | 1.640 |
Why?
|
| Pregnancy Complications, Infectious | 11 | 2021 | 491 | 1.520 |
Why?
|
| Child Health Services | 5 | 2018 | 88 | 1.260 |
Why?
|
| Mass Screening | 7 | 2020 | 837 | 1.070 |
Why?
|
| Anti-HIV Agents | 15 | 2023 | 350 | 1.020 |
Why?
|
| Counseling | 7 | 2023 | 240 | 1.020 |
Why?
|
| Health Personnel | 8 | 2021 | 544 | 1.010 |
Why?
|
| Tuberculosis | 4 | 2020 | 553 | 0.860 |
Why?
|
| Burnout, Professional | 2 | 2019 | 130 | 0.660 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2016 | 272 | 0.660 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2018 | 236 | 0.650 |
Why?
|
| Community Health Workers | 4 | 2017 | 76 | 0.610 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2017 | 42 | 0.550 |
Why?
|
| Family Characteristics | 1 | 2017 | 91 | 0.520 |
Why?
|
| Community Health Services | 1 | 2017 | 93 | 0.510 |
Why?
|
| Infection Control | 1 | 2017 | 161 | 0.510 |
Why?
|
| Quality of Health Care | 2 | 2018 | 423 | 0.500 |
Why?
|
| Health Policy | 1 | 2018 | 233 | 0.490 |
Why?
|
| Chemoprevention | 1 | 2015 | 54 | 0.470 |
Why?
|
| Antitubercular Agents | 2 | 2016 | 265 | 0.460 |
Why?
|
| Ambulatory Care Facilities | 2 | 2017 | 241 | 0.450 |
Why?
|
| Cross Infection | 1 | 2017 | 344 | 0.440 |
Why?
|
| Hearing Loss | 1 | 2016 | 214 | 0.430 |
Why?
|
| Social Work | 1 | 2013 | 21 | 0.420 |
Why?
|
| Pregnancy | 18 | 2023 | 7599 | 0.410 |
Why?
|
| Breast Feeding | 2 | 2023 | 240 | 0.410 |
Why?
|
| Child | 24 | 2022 | 25863 | 0.380 |
Why?
|
| Sarcoma, Kaposi | 3 | 2018 | 136 | 0.370 |
Why?
|
| Adolescent | 19 | 2022 | 20569 | 0.330 |
Why?
|
| Medication Adherence | 5 | 2023 | 343 | 0.320 |
Why?
|
| Humans | 47 | 2024 | 133331 | 0.320 |
Why?
|
| Female | 35 | 2023 | 71482 | 0.300 |
Why?
|
| Child, Preschool | 15 | 2019 | 14872 | 0.300 |
Why?
|
| AIDS Serodiagnosis | 3 | 2019 | 57 | 0.290 |
Why?
|
| Infant | 16 | 2019 | 13241 | 0.270 |
Why?
|
| Leishmania infantum | 2 | 2006 | 3 | 0.270 |
Why?
|
| Leishmaniasis, Visceral | 2 | 2006 | 20 | 0.260 |
Why?
|
| Early Diagnosis | 3 | 2018 | 199 | 0.260 |
Why?
|
| Developing Countries | 2 | 2022 | 290 | 0.260 |
Why?
|
| Adult | 18 | 2023 | 31674 | 0.250 |
Why?
|
| Protozoan Vaccines | 2 | 2006 | 96 | 0.250 |
Why?
|
| Africa South of the Sahara | 3 | 2020 | 129 | 0.240 |
Why?
|
| Depression | 4 | 2022 | 1362 | 0.230 |
Why?
|
| Cross-Sectional Studies | 6 | 2022 | 3731 | 0.230 |
Why?
|
| Male | 24 | 2019 | 65576 | 0.230 |
Why?
|
| Long-Term Care | 2 | 2013 | 72 | 0.210 |
Why?
|
| Preventive Health Services | 2 | 2013 | 62 | 0.200 |
Why?
|
| Coinfection | 2 | 2016 | 182 | 0.200 |
Why?
|
| Infant, Newborn | 8 | 2021 | 8630 | 0.190 |
Why?
|
| Noncommunicable Diseases | 1 | 2022 | 18 | 0.190 |
Why?
|
| Health Services Accessibility | 3 | 2017 | 658 | 0.180 |
Why?
|
| Intimate Partner Violence | 1 | 2021 | 29 | 0.180 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2013 | 138 | 0.170 |
Why?
|
| Audiovisual Aids | 1 | 2020 | 23 | 0.160 |
Why?
|
| Type D Personality | 1 | 2019 | 3 | 0.160 |
Why?
|
| Viral Load | 2 | 2018 | 411 | 0.160 |
Why?
|
| Marital Status | 1 | 2019 | 32 | 0.160 |
Why?
|
| Young Adult | 8 | 2019 | 9920 | 0.160 |
Why?
|
| Job Satisfaction | 1 | 2019 | 93 | 0.150 |
Why?
|
| Pediatrics | 2 | 2018 | 1221 | 0.150 |
Why?
|
| Syphilis | 1 | 2019 | 98 | 0.150 |
Why?
|
| Multivariate Analysis | 3 | 2018 | 1463 | 0.150 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 2142 | 0.140 |
Why?
|
| Herpesviridae Infections | 1 | 2018 | 146 | 0.140 |
Why?
|
| Health Services Research | 1 | 2018 | 189 | 0.130 |
Why?
|
| Audiometry, Pure-Tone | 1 | 2016 | 25 | 0.130 |
Why?
|
| Interleukin-6 | 1 | 2018 | 439 | 0.130 |
Why?
|
| Risk Factors | 4 | 2019 | 10951 | 0.120 |
Why?
|
| Odds Ratio | 2 | 2016 | 1253 | 0.120 |
Why?
|
| Sex Factors | 1 | 2019 | 1353 | 0.120 |
Why?
|
| Self Report | 4 | 2020 | 553 | 0.120 |
Why?
|
| Risk Assessment | 2 | 2016 | 3718 | 0.120 |
Why?
|
| Infant Mortality | 2 | 2013 | 180 | 0.120 |
Why?
|
| Surveys and Questionnaires | 3 | 2021 | 3982 | 0.120 |
Why?
|
| Family | 1 | 2018 | 593 | 0.120 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 593 | 0.120 |
Why?
|
| Prevalence | 2 | 2019 | 2628 | 0.110 |
Why?
|
| Mental Disorders | 1 | 2022 | 891 | 0.110 |
Why?
|
| Antigens, Protozoan | 2 | 2006 | 80 | 0.110 |
Why?
|
| Maternal Health Services | 2 | 2013 | 43 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 480 | 0.110 |
Why?
|
| Cause of Death | 1 | 2016 | 504 | 0.110 |
Why?
|
| Drug Utilization | 1 | 2015 | 169 | 0.110 |
Why?
|
| Child Mortality | 1 | 2013 | 26 | 0.110 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2017 | 408 | 0.100 |
Why?
|
| Public Health | 1 | 2016 | 283 | 0.100 |
Why?
|
| Public Policy | 1 | 2013 | 54 | 0.100 |
Why?
|
| Child, Orphaned | 1 | 2013 | 21 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 1137 | 0.100 |
Why?
|
| Immunization Programs | 1 | 2013 | 65 | 0.100 |
Why?
|
| CD4 Lymphocyte Count | 4 | 2013 | 237 | 0.100 |
Why?
|
| Health Resources | 1 | 2013 | 127 | 0.100 |
Why?
|
| Malnutrition | 2 | 2013 | 221 | 0.100 |
Why?
|
| Age Factors | 2 | 2016 | 2956 | 0.100 |
Why?
|
| Vulnerable Populations | 1 | 2013 | 148 | 0.090 |
Why?
|
| Disease Models, Animal | 1 | 2003 | 4760 | 0.090 |
Why?
|
| Quality Assurance, Health Care | 1 | 2013 | 221 | 0.090 |
Why?
|
| Time Factors | 3 | 2016 | 6544 | 0.090 |
Why?
|
| Lost to Follow-Up | 3 | 2018 | 33 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2016 | 13103 | 0.090 |
Why?
|
| Social Support | 1 | 2013 | 388 | 0.090 |
Why?
|
| Population Surveillance | 1 | 2013 | 416 | 0.090 |
Why?
|
| Psychometrics | 1 | 2014 | 690 | 0.080 |
Why?
|
| Health Care Costs | 1 | 2013 | 409 | 0.080 |
Why?
|
| Contact Tracing | 2 | 2021 | 56 | 0.080 |
Why?
|
| Treatment Adherence and Compliance | 2 | 2020 | 11 | 0.080 |
Why?
|
| Video Recording | 2 | 2023 | 203 | 0.080 |
Why?
|
| Pilot Projects | 3 | 2021 | 1469 | 0.080 |
Why?
|
| Electronic Health Records | 1 | 2016 | 804 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 1353 | 0.070 |
Why?
|
| Capacity Building | 2 | 2021 | 25 | 0.070 |
Why?
|
| Retrospective Studies | 6 | 2016 | 17568 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 1583 | 0.070 |
Why?
|
| Pregnancy Complications | 1 | 2012 | 553 | 0.070 |
Why?
|
| Quality of Life | 1 | 2016 | 2161 | 0.060 |
Why?
|
| Dog Diseases | 1 | 2006 | 58 | 0.060 |
Why?
|
| Disclosure | 2 | 2017 | 155 | 0.060 |
Why?
|
| Logistic Models | 3 | 2017 | 1864 | 0.060 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2018 | 855 | 0.050 |
Why?
|
| World Health Organization | 2 | 2013 | 119 | 0.050 |
Why?
|
| Prenatal Care | 2 | 2019 | 360 | 0.050 |
Why?
|
| Administration, Cutaneous | 1 | 2003 | 68 | 0.050 |
Why?
|
| Lymphoid Tissue | 1 | 2003 | 44 | 0.050 |
Why?
|
| Program Development | 2 | 2013 | 190 | 0.050 |
Why?
|
| Injections, Intravenous | 1 | 2003 | 251 | 0.050 |
Why?
|
| Virulence | 1 | 2003 | 278 | 0.050 |
Why?
|
| Income | 1 | 2022 | 139 | 0.050 |
Why?
|
| Nutritional Status | 2 | 2013 | 325 | 0.040 |
Why?
|
| Tanzania | 1 | 2020 | 73 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2003 | 1083 | 0.040 |
Why?
|
| HIV-1 | 2 | 2016 | 489 | 0.040 |
Why?
|
| Skin | 1 | 2003 | 542 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2020 | 294 | 0.040 |
Why?
|
| Sexual Partners | 1 | 2019 | 86 | 0.040 |
Why?
|
| Poverty | 1 | 2022 | 438 | 0.040 |
Why?
|
| Endemic Diseases | 1 | 2018 | 59 | 0.040 |
Why?
|
| Global Health | 2 | 2013 | 622 | 0.040 |
Why?
|
| Healthcare Disparities | 2 | 2013 | 484 | 0.040 |
Why?
|
| Herpesvirus 8, Human | 1 | 2018 | 52 | 0.040 |
Why?
|
| Family Health | 1 | 2019 | 258 | 0.040 |
Why?
|
| Depersonalization | 1 | 2018 | 10 | 0.040 |
Why?
|
| Virus Activation | 1 | 2018 | 85 | 0.040 |
Why?
|
| Africa | 1 | 2018 | 140 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 135 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2022 | 1235 | 0.030 |
Why?
|
| Stereotyping | 1 | 2017 | 20 | 0.030 |
Why?
|
| Drug Prescriptions | 1 | 2018 | 244 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2018 | 809 | 0.030 |
Why?
|
| Bleomycin | 1 | 2016 | 114 | 0.030 |
Why?
|
| Pregnancy Outcome | 1 | 2019 | 637 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 681 | 0.030 |
Why?
|
| Risk | 1 | 2017 | 782 | 0.030 |
Why?
|
| Bullying | 1 | 2015 | 19 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2015 | 101 | 0.030 |
Why?
|
| Remission Induction | 1 | 2016 | 307 | 0.030 |
Why?
|
| Vincristine | 1 | 2016 | 196 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 1213 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2018 | 1584 | 0.030 |
Why?
|
| United Nations | 1 | 2013 | 12 | 0.030 |
Why?
|
| Urban Health | 1 | 2013 | 78 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 1364 | 0.030 |
Why?
|
| Schools | 1 | 2015 | 237 | 0.030 |
Why?
|
| Premedication | 1 | 2013 | 42 | 0.030 |
Why?
|
| Lesotho | 1 | 2012 | 17 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 908 | 0.020 |
Why?
|
| ROC Curve | 1 | 2014 | 606 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2013 | 276 | 0.020 |
Why?
|
| Community Networks | 1 | 2012 | 33 | 0.020 |
Why?
|
| Outpatients | 1 | 2014 | 275 | 0.020 |
Why?
|
| Mental Health | 1 | 2015 | 373 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 722 | 0.020 |
Why?
|
| Food, Formulated | 1 | 2012 | 52 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2013 | 396 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 965 | 0.020 |
Why?
|
| Health Planning Guidelines | 1 | 2011 | 34 | 0.020 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2013 | 243 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 562 | 0.020 |
Why?
|
| HIV Antibodies | 1 | 2011 | 71 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2013 | 477 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2012 | 457 | 0.020 |
Why?
|
| Health Promotion | 1 | 2013 | 403 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 2288 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 1310 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 1513 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2013 | 728 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2018 | 6582 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 5443 | 0.020 |
Why?
|
| Antibodies, Protozoan | 1 | 2006 | 95 | 0.020 |
Why?
|
| Prognosis | 1 | 2016 | 5044 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2006 | 159 | 0.020 |
Why?
|
| Dogs | 1 | 2006 | 672 | 0.010 |
Why?
|
| Mice | 1 | 2003 | 18936 | 0.010 |
Why?
|
| Animals | 2 | 2006 | 36217 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2006 | 356 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2006 | 687 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2006 | 536 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2006 | 684 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2011 | 5199 | 0.010 |
Why?
|
| Cytokines | 1 | 2006 | 1378 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2006 | 2877 | 0.010 |
Why?
|